Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Authors:
Rik Vandenberghe, MD, PhD
Rik Vandenberghe, MD, PhD
Katholieke Universiteit Leuven
Professor in Neurology
Cognitive Neurology
Leuven | Belgium

Ann Neurol 2018 11;84(5):729-740

Alzheimer center Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, VU University, Amsterdam, the Netherlands.

Objective: To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants.

Methods: We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models.

Results: Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001). Prevalence of amyloid-β positivity increased with age in nfvPPA (from 10% at age 50 years to 27% at age 80 years, p < 0.01) and svPPA (from 6% at age 50 years to 32% at age 80 years, p < 0.001), but not in lvPPA (p = 0.94). Across PPA variants, ApoE ε4 carriers were more often amyloid-β positive (58.0%) than noncarriers (35.0%, p < 0.001). Autopsy data revealed Alzheimer disease pathology as the most common pathologic diagnosis in lvPPA (76%), frontotemporal lobar degeneration-TDP-43 in svPPA (80%), and frontotemporal lobar degeneration-TDP-43/tau in nfvPPA (64%).

Interpretation: This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid-β biomarkers in PPA patients. Ann Neurol 2018;84:737-748.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354051PMC
November 2018
32 Reads
9.980 Impact Factor

Publication Analysis

Top Keywords

prevalence amyloid
8
amyloid positivity
8
primary progressive
8
progressive aphasia
8
amyloid-β pathology
8
[lvppa n = 443]
4
positivity ppa
4
determined generalized
4
logopenic [lvppa
4
meta-analysis individual
4
n = 443] nonfluent
4
n = 333] semantic
4
[nfvppa n = 333]
4
status determined
4
nonfluent [nfvppa
4
including logopenic
4
ppa including
4
data 1251
4
equation modelsresults
4
participant data
4

References

(Supplied by CrossRef)
Alzheimer's disease presenting as slowly progressive aphasia
Pogacar et al.
R I Med J 1984
Primary progressive aphasia
Mesulam et al.
Ann Neurol 2001

Similar Publications